Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

Ian E. Krop, Thomas M. Suter, Chau T. Dang, Luc Dirix, Gilles Romieu, Claudio Zamagni, Marc L. Citron, Mario Campone, Na Xu, Melanie Smitt, Luca Gianni

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences